cA2 data

CNTO presented data from a Phase II European trial of cA2 in patients with methotrexate-resistant RA at the International League of Associations for Rheumatology conference in Singapore. A total of 103 patients received either 7.5 mg/week methotrexate plus placebo, or methotrexate with

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE